Phase II trial of neoadjuvant and adjuvant capmatinib in participants with stages IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) NSCLC with MET exon 14 skipping mutation or high MET amplification Geometry-N
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this research study is to find out if a drug called capmatinib is safe and effective (can help people) in people who have non-small cell lung cancer (NSCLC) who are also eligible for surgery. Capmatinib is an oral drug that targets particular processes, which may not be working properly in the cancer cells (dysregulation) in the body. Prior to surgery, participants will receive two cycles (a treatment cycle is 4 weeks long) of capmatinib. After the two cycles are complete, participants will undergo surgery to remove their cancer. After surgery, the Study Doctor may or may not prescribe chemotherapy before starting capmatinib treatment again.
This study is closed
Catherine Shu, MD
|Are you at least 18 years old?
|Have you been diagnosed with non-small cell lung cancer (NSCLC) and it's able to be removed by surgery?
|Are you willing to follow the scheduled study visits, treatment plans, and have extra laboratory tests?